Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

Who May Qualify: - willing to sign a consent form as documented by signature - Severe AS and scheduled for transfemoral TAVI Who Should NOT Join This Trial: - Contraindications to the class of drugs under study (C1INH), e.g., known hypersensitivity or allergy to class of drugs or the investigational product - History of allergy to rabbits (as rhC1INH is derived from the breast milk of transgenic rabbits) - Women who are pregnant or breast feeding - Hemodynamic instability requiring emergency TAVI - Valve-in-valve procedure - Other access route than transfemoral - Non-cardiac co-morbidity with expected survival \<6 months - Ischemic or hemorrhagic stroke within 30 days before TAVI - Dialysis or estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73m2 - Contraindication for MRI such as a permanent non-MRI compatible pacemaker or severe claustrophobia - Liver cirrhosis (any Child-Pugh score) - Incapacity or inability to provide willing to sign a consent form - Participation in another study with investigational drug or medical device within the 30 days preceding and during the present study - Previous enrolment into the current study - Any uncontrolled or significant concurrent illness that would put the patient at a greater risk or limit compliance with the study requirements at the discretion of the investigator Always talk to your doctor about whether this trial is right for you.